Rich Pharmaceuticals Inc. (fka RCHA)

[Moni001]

Rich Pharmaceuticals Explains How Targeted Immunotherapy Aids in the Treatment and Recovery of AML Patients
April 10, 2018 07:00 ET | Source: Rich Pharmaceuticals
BEVERLY HILLS, CA , April 10, 2018 (GLOBE NEWSWIRE) -- Rich Pharmaceuticals, Inc. (OTC: RCHA), a Biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology, discusses how its Targeted Immunotherapy works in conjunction with patient’s immune system to help aid in the treatment of Acute Myelogenous Leukemia (AML).

Rich Pharmaceuticals is working toward clinical trials using its Targeted Immunotherapy approach that aids in defending the body against cancer. Its drug, TPA, helps boosts the body’s natural immune system. TPA has been known for many years to be one of the most potent differentiation agents know to science, able to modulate the growth, survival, function and metabolism of a variety of primary cells and cell lines. The mitogen activity of TPA results from it being a signaling agent to the nucleus to perform targeted actions. In addition to the induction of differentiation, TPA has been demonstrated to modulate the growth, survival, function and metabolism of a variety of primary cells and cell lines. This broad range of mediated biologic effects is what allows one to classify TPA use as an immunotherapy.

In 2016, more than 60,000 cases of leukemia were expected to be reported, with more than 4,000 deaths expected to occur. Current leukemia survival rates in the US vary from subtype to subtype, ranging from 26.6% to 82.6%. In most cases of leukemia, chemotherapy is the first line of treatment for this disease, though some patients require stem cell transplant therapies to eliminate the leukemia entirely. What Rich Pharmaceuticals is attempting to do is to introduce a new drug allowing the body’s immune system to take a much more vigorous role in battling the cancer.

AMLis an aggressive disease that requires urgent and intensive therapy. Patients diagnosed with AML are, on average, between 64 and 68 years of age. Patients over 60 treated with standard chemotherapy are cured of their disease less that 20 percent of the time. In addition, patients who develop AML after an antecedent hematologic disorder or prior leukemogenic chemotherapy/radiation have similarly poor outcomes as do patients whose disease is associated with specific cytogenetic and clinical features.